What are the differences in symptoms between mild autonomous cortisol secretion (MACS) and Cushing syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

The Key Difference: MACS Lacks the Classic Physical Signs of Cushing's Syndrome

The fundamental difference between MACS (Mild Autonomous Cortisol Secretion) and Cushing's syndrome is that MACS patients have biochemical evidence of autonomous cortisol production WITHOUT the overt, characteristic physical features of Cushing's syndrome, while Cushing's syndrome patients display the classic clinical stigmata of hypercortisolism 1.

Clinical Presentation Differences

Cushing's Syndrome - Distinctive Physical Features Present

Cushing's syndrome patients exhibit discriminatory clinical signs that are relatively specific 2:

  • Reddish-purple striae (especially if >1 cm wide)
  • Facial plethora (facial redness)
  • Proximal muscle weakness or myopathy
  • Easy bruising without obvious trauma
  • Thin, fragile skin
  • Central obesity with supraclavicular fat pads and dorsocervical fat pad ("buffalo hump")
  • Unexplained osteoporosis

These physical findings, when present together, make Cushing's syndrome "clinically unmistakable when full blown" 2.

MACS - Physical Features Conspicuously Absent

MACS is explicitly defined by the ABSENCE of these overt clinical features 1. The AACE/AAES guidelines specifically state that MACS is characterized by "no overt clinical features of Cushing syndrome such as atypical fat redistribution, skin fragility, or proximal muscle weakness" 1.

However, this creates a diagnostic challenge: recent research shows significant overlap exists 3. A 2024 study found that 28% of patients with overt Cushing's syndrome had only 0-3 clinical signs, while MACS patients averaged 2 clinical signs (range 1-3) 3. This means some Cushing's patients may appear relatively mild, while some MACS patients may have subtle features.

Metabolic Comorbidities - The Surprising Similarity

Here's a critical clinical pitfall: the frequency and severity of metabolic comorbidities are remarkably similar between MACS and Cushing's syndrome, despite the difference in physical appearance 3, 4, 5:

Both Conditions Present With:

  • Hypertension (78-92% in Cushing's, 87% in MACS) 3
  • Type 2 diabetes mellitus
  • Dyslipidemia
  • Obesity
  • Osteoporosis
  • Increased cardiovascular risk

The 2024 study found patients with Cushing's syndrome had an average of 2 comorbidities (range 1-3), while MACS patients actually had 3 comorbidities (range 2-3) 3. Even more striking, a 2026 study demonstrated that metabolic parameters and left ventricular mass index were NOT significantly different between MACS and Cushing's syndrome 4.

Biochemical Differences - Degree, Not Kind

The biochemical distinction is primarily one of magnitude rather than pattern:

Cortisol Levels

  • Cushing's syndrome: Markedly elevated 24-hour urinary free cortisol (UFC), often >4 times the upper limit of normal 1
  • MACS: Subtle cortisol elevation, UFC may be normal or mildly elevated 1

Dexamethasone Suppression Test

  • Cushing's syndrome: Post-1mg DST cortisol typically >5 μg/dL, often much higher 1
  • MACS: Post-1mg DST cortisol >1.8 μg/dL but often <5 μg/dL 1

ACTH Levels

Both show suppressed or low ACTH (in adrenal causes), confirming ACTH-independent cortisol production 1.

Psychological and Quality of Life Impact

An often-overlooked difference: both conditions significantly impair quality of life, but through different mechanisms 6:

  • Cushing's syndrome: Obvious physical changes cause psychological distress
  • MACS: Despite minimal physical changes, patients show impaired quality of life across most SF-36 domains compared to population norms, with mild depressive and anxiety symptoms 6

The Clinical Algorithm for Differentiation

When evaluating a patient with autonomous cortisol secretion:

  1. Look for the discriminatory physical signs (purple striae >1cm, facial plethora, proximal myopathy, easy bruising, thin skin)

    • Present → Likely Cushing's syndrome
    • Absent → Likely MACS

  2. Check cortisol levels:

    • Post-1mg DST >5 μg/dL → Cushing's syndrome
    • Post-1mg DST 1.8-5 μg/dL → MACS territory
    • 24-hour UFC >4x normal → Cushing's syndrome

  3. Count metabolic comorbidities - This does NOT distinguish them (both have similar burden)

  4. The definitive proof for MACS: Development of adrenal insufficiency after adrenalectomy 1

Critical Clinical Caveat

Do not be falsely reassured by the absence of classic Cushing's features - MACS still carries significant morbidity. The 2023 CUA guideline notes that MACS is associated with type 2 diabetes, hypertension, cardiovascular events, vertebral fractures, and mortality 7. The term "subclinical" is misleading; these patients are not asymptomatic, they simply lack the pathognomonic physical stigmata 1.

The progression risk is low: MACS rarely progresses to overt Cushing's syndrome (rare event within 1-7 years) 1, but the metabolic damage accumulates regardless 3, 4.

References

1
Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

2
Guideline

the diagnosis of cushing's syndrome: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2008

6
Research

Psychological Burden in Mild Autonomous Cortisol Secretion: A Cross-Sectional Comparative Study.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2026

Related Questions

In a postmenopausal woman with a history of Cushing's disease, primary aldosteronism (Conn's syndrome), mild autonomous cortisol secretion (MACS), and adrenalectomy 10 weeks ago, are total testosterone of 232.86 ng/dL and free testosterone of 2.7 ng/dL dangerous, and what are the possible causes, symptoms, and recommended next steps?
Is a cortisol level of 1.59 µg/dL after a low‑dose dexamethasone suppression test considered normal and does it rule out Cushing syndrome?
What is the precise medical term for Cushing syndrome and how is the term broken down into its word components?
Is medical management of mild autonomous cortisol secretion with cortisol‑lowering drugs an established treatment, and when should it be used?
What are the differences between Cushing's syndrome and dysautonomia (Dysautonomic syndrome)?
I am taking Clarium (piribedil) for Parkinson's disease and feel unusually tired; could this be a side effect and how should I manage it?
What is the appropriate administration timing for Humulin R (regular insulin) using a sliding‑scale protocol?
For a patient traveling abroad without access to healthcare or refrigeration, who can take tablets or liquid, which is the preferred regimen—amoxicillin 875 mg twice daily for 10 days or amoxicillin‑clavulanate (Augmentin) 875 mg/125 mg twice daily for 10 days?
What is the recommended titration schedule for clozapine in adults?
What are the postoperative complications following a laparoscopic appendectomy?
Can a patient with a family history of pancreatic cancer safely use GLP‑1 receptor agonists?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.